Logo image of TOI

ONCOLOGY INSTITUTE INC/THE (TOI) Stock Fundamental Analysis

NASDAQ:TOI - Nasdaq - US68236X1000 - Common Stock - Currency: USD

0.8492  -0.03 (-3.5%)

After market: 0.84 -0.01 (-1.08%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to TOI. TOI was compared to 109 industry peers in the Health Care Providers & Services industry. TOI has a bad profitability rating. Also its financial health evaluation is rather negative. TOI is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year TOI has reported negative net income.
TOI had a negative operating cash flow in the past year.
In the past 5 years TOI reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: TOI reported negative operating cash flow in multiple years.
TOI Yearly Net Income VS EBIT VS OCF VS FCFTOI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 -20M -40M -60M

1.2 Ratios

The Return On Assets of TOI (-32.07%) is worse than 85.19% of its industry peers.
Looking at the Return On Equity, with a value of -371.14%, TOI is doing worse than 85.19% of the companies in the same industry.
Industry RankSector Rank
ROA -32.07%
ROE -371.14%
ROIC N/A
ROA(3y)-12.59%
ROA(5y)-13.25%
ROE(3y)-43.14%
ROE(5y)-37.96%
ROIC(3y)N/A
ROIC(5y)N/A
TOI Yearly ROA, ROE, ROICTOI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 -20 -40 -60 -80 -100

1.3 Margins

TOI has a worse Gross Margin (14.18%) than 75.00% of its industry peers.
In the last couple of years the Gross Margin of TOI has declined.
The Profit Margin and Operating Margin are not available for TOI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 14.18%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.26%
GM growth 5Y-4.59%
TOI Yearly Profit, Operating, Gross MarginsTOI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 10 -10 20 -20

More info and screens

3

2. Health

2.1 Basic Checks

TOI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TOI has been increased compared to 1 year ago.
TOI has a worse debt/assets ratio than last year.
TOI Yearly Shares OutstandingTOI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 20M 40M 60M
TOI Yearly Total Debt VS Total AssetsTOI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of 0.11, we must say that TOI is in the distress zone and has some risk of bankruptcy.
TOI has a worse Altman-Z score (0.11) than 72.22% of its industry peers.
A Debt/Equity ratio of 5.91 is on the high side and indicates that TOI has dependencies on debt financing.
The Debt to Equity ratio of TOI (5.91) is worse than 85.19% of its industry peers.
Industry RankSector Rank
Debt/Equity 5.91
Debt/FCF N/A
Altman-Z 0.11
ROIC/WACCN/A
WACC7.35%
TOI Yearly LT Debt VS Equity VS FCFTOI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 2.49 indicates that TOI has no problem at all paying its short term obligations.
TOI has a Current ratio of 2.49. This is amongst the best in the industry. TOI outperforms 81.48% of its industry peers.
A Quick Ratio of 2.27 indicates that TOI has no problem at all paying its short term obligations.
TOI has a Quick ratio of 2.27. This is in the better half of the industry: TOI outperforms 79.63% of its industry peers.
Industry RankSector Rank
Current Ratio 2.49
Quick Ratio 2.27
TOI Yearly Current Assets VS Current LiabilitesTOI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

7

3. Growth

3.1 Past

TOI shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.85%.
TOI shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.29%.
Measured over the past years, TOI shows a very strong growth in Revenue. The Revenue has been growing by 23.43% on average per year.
EPS 1Y (TTM)-6.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.26%
Revenue 1Y (TTM)22.29%
Revenue growth 3Y20.03%
Revenue growth 5Y23.43%
Sales Q2Q%21.78%

3.2 Future

Based on estimates for the next years, TOI will show a very strong growth in Earnings Per Share. The EPS will grow by 32.88% on average per year.
The Revenue is expected to grow by 22.73% on average over the next years. This is a very strong growth
EPS Next Y38.52%
EPS Next 2Y32.88%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year29.38%
Revenue Next 2Y22.73%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
TOI Yearly Revenue VS EstimatesTOI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M
TOI Yearly EPS VS EstimatesTOI Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 -0.2 -0.4 -0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TOI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TOI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TOI Price Earnings VS Forward Price EarningsTOI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TOI Per share dataTOI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4 5

4.3 Compensation for Growth

TOI's earnings are expected to grow with 32.88% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.88%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

TOI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ONCOLOGY INSTITUTE INC/THE

NASDAQ:TOI (2/5/2025, 8:00:01 PM)

After market: 0.84 -0.01 (-1.08%)

0.8492

-0.03 (-3.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)N/A N/A
Inst Owners45.02%
Inst Owner Change0.71%
Ins Owners2.83%
Ins Owner Change2.22%
Market Cap64.17M
Analysts84
Price Target2.04 (140.23%)
Short Float %0.58%
Short Ratio0.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-132.67%
Min EPS beat(2)-197.03%
Max EPS beat(2)-68.32%
EPS beat(4)0
Avg EPS beat(4)-108.97%
Min EPS beat(4)-197.03%
Max EPS beat(4)-68.32%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-6.78%
Min Revenue beat(2)-8.03%
Max Revenue beat(2)-5.52%
Revenue beat(4)1
Avg Revenue beat(4)-2.88%
Min Revenue beat(4)-8.03%
Max Revenue beat(4)3.53%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.17
P/FCF N/A
P/OCF N/A
P/B 4.14
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.78
EYN/A
EPS(NY)-0.16
Fwd EYN/A
FCF(TTM)-0.5
FCFYN/A
OCF(TTM)-0.46
OCFYN/A
SpS5.01
BVpS0.2
TBVpS-0.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -32.07%
ROE -371.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 14.18%
FCFM N/A
ROA(3y)-12.59%
ROA(5y)-13.25%
ROE(3y)-43.14%
ROE(5y)-37.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.26%
GM growth 5Y-4.59%
F-Score2
Asset Turnover2.11
Health
Industry RankSector Rank
Debt/Equity 5.91
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 46.99%
Cap/Sales 0.76%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.49
Quick Ratio 2.27
Altman-Z 0.11
F-Score2
WACC7.35%
ROIC/WACCN/A
Cap/Depr(3y)98.16%
Cap/Depr(5y)74.54%
Cap/Sales(3y)1.7%
Cap/Sales(5y)1.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.26%
EPS Next Y38.52%
EPS Next 2Y32.88%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)22.29%
Revenue growth 3Y20.03%
Revenue growth 5Y23.43%
Sales Q2Q%21.78%
Revenue Next Year29.38%
Revenue Next 2Y22.73%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-5.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.74%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y50.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.31%
OCF growth 3YN/A
OCF growth 5YN/A